Neil P. DiSpirito

Hear directly from FDA’s CBER Center Director and learn about the latest policy developments, enforcement actions, and priority initiatives for 2017. An industry panel moderated by Mr. DiSpirito will follow, along with questions from the audience. This session will specifically focus on regenerative advanced therapy designation.

For more information, click here.